×
About 9,040 results

ALLMedicine™ Myeloma Center

Research & Reviews  3,520 results

Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple ...
https://doi.org/10.1016/j.blre.2022.100986
Blood Reviews; Meier J, Jensen JL et. al.

Jun 27th, 2022 - Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cance...

Corneal toxicity associated with belantamab mafodotin is not restricted to the epitheli...
https://doi.org/10.1016/j.ajo.2022.06.009
American Journal of Ophthalmology; Aschauer J, Donner R et. al.

Jun 26th, 2022 - The purpose of this study was to investigate epithelial and neuronal changes in patients with refractory/relapsed multiple myeloma (RRMM) before/during belantamab mafodotin (belamaf) treatment using confocal microscopy. Retrospective case series. ...

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antige...
https://doi.org/10.1158/1535-7163.MCT-21-0552
Molecular Cancer Therapeutics; Buonato JM, Edwards JP et. al.

Jun 24th, 2022 - Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior reported CAR T...

Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.
https://doi.org/10.1136/bcr-2022-249637
BMJ Case Reports; Puliafito B, Oveisi D et. al.

Jun 23rd, 2022 - Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies. We present a case of a patient with IgG kappa MM undergoing treatment f...

Chromosome 1q21 Aberrations Identify Ultra High-Risk Myeloma with Prognostic and Clinic...
https://doi.org/10.1002/ajh.26639
American Journal of Hematology; Kastritis E, Migkou M et. al.

Jun 23rd, 2022 - Numerical abnormalities of chromosome 1q (+1q21) are common in patients with newly diagnosed multiple myeloma (MM) but their prognostic impact remains a matter of debate. In addition, the impact of the number of copies of 1q21 is not known. We ana...

see more →

Guidelines  11 results

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive C...
https://doi.org/10.1016/j.clml.2021.07.028
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patien...
https://doi.org/10.1111/joim.12882
Journal of Internal Medicine; Bringhen S, Milan A et. al.

Feb 7th, 2019 - The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed M...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891187
Journal of the National Comprehensive Cancer Network : JN... Anderson KC, Alsina M et. al.

Nov 11th, 2015 - Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The N...

see more →

Drugs  22 results see all →

News  57 results

Skill Checkup: An Elderly Man With Leg Pain and Weakness
https://www.medscape.com/viewarticle/962962

Apr 4th, 2022 - The Skill Checkup series provides a quick, case-style interactive quiz highlighting key guidelines- and evidence-based information to inform clinical practice. A 79-year-old retired White male schoolteacher presents with bone pain and increasing w...

Five-Drug Combination Shows Benefit in Ultra-High Risk Multiple Myeloma
https://www.medscape.com/viewarticle/964787

Dec 14th, 2021 - A team of researchers from The Institute of Cancer Research in London and the Clinical Trials Research Unit at the University of Leeds has identified a new five-drug combination that significantly improves progression-free survival (PFS) in patien...

New Trials in Lymphoma and MM: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962201

Nov 3rd, 2021 - A number of late-phase clinical trials in lymphoma and multiple myeloma (MM) have opened in recent months. Maybe one of your patients could benefit from being enrolled? Untreated peripheral T-cell lymphoma. Adult patients with peripheral T-cell ly...

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Apr 1st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

Assessing Measurable Residual Disease Tied to Better Outcome in Multiple Myeloma
https://www.medscape.com/viewarticle/943007

Dec 22nd, 2020 - NEW YORK (Reuters Health) - Clinical decision-making based on assessment of measurable residual disease (MRD) is associated with better outcome in patients with multiple myeloma (MM), a real-world study indicates. Patients who were MRD negative, a...

see more →

Patient Education  6 results see all →